To provide state-of-the art care and treatment for cancer and blood disorders with your convenience and lifestyle in mind, Regional Cancer Care Associates has more than 25 locations throughout New Jersey, Connecticut, Maryland, and the Washington, D.C. area. Use our Find A Location function or find a city near you in the lists below.
To provide state-of-the art care and treatment for cancer and blood disorders with your convenience and lifestyle in mind, Regional Cancer Care Associates has more than 25 locations throughout New Jersey, Connecticut, Maryland, and the Washington, DC area. Use our Find A Location function or find a city near you in the lists below.
We’re here for you. Call us at 844-346-7222 or
The Freehold, NJ office of Regional Cancer Care Associates (RCCA) is now offering the targeted therapy Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to patients with metastatic castration-resistant prostate cancer (mCRPC) that is positive for prostate-specific membrane antigen (PSMA).
mCRPC is an advanced form of prostate cancer that has spread to other parts of the body and that is no longer responding to hormone treatment given to reduce levels of testosterone, the male sex hormone that fuels prostate cancer growth. PSMA is a biomarker that is expressed on prostate cancer cells and that can be seen on an imaging test called PSMA positron emission tomography, or PSMA PET.
Pluvicto attaches to PSMA and then is absorbed by cells that express the biomarker. Once absorbed into those cells, Pluvicto releases radiation that can damage and kill cells that are PSMA-positive and other nearby cells.
The Food and Drug Administration (FDA) approved Pluvicto for use in PSMA-positive mCRPC in March 2022 after the Phase 3 VISION trial showed that patients with PSMA+ mCRPC who received Pluvicto had longer survival than men receiving standard therapies. The most common side effects seen with Pluvicto include tiredness, dry mouth, nausea, low red blood cell counts, and loss of appetite, among others.
Pluvicto is given via intravenous (IV) injection or infusion approximately every 6 weeks for up to 6 treatments. The targeted therapy typically is given after mCRPC patients have experienced disease progression on other treatments, such as hormone therapy and chemotherapy. Before starting the treatment, patients must have imaging tests to confirm that they have PSMA-positive cancer cells. Patients also must take certain precautions during and following treatment.
To learn more about Pluvicto and the full range of treatments and clinical trials that the Freehold office of RCCA offers for people with solid tumors, hematologic malignancies, and non-cancerous blood disorders, call 732-479-8580.
Phone: 973-751-8880
Phone: (609) 536-8414
Phone: (908) 755-1165
Phone: (732) 431-8400
Phone: (551) 996-5900
Phone: (732) 739-8644
Phone: (732) 367-1535
Phone: (732) 530-8666
Phone: (609) 390-7888
Phone: 973-744-8000
Phone: (609) 702-1900
Phone: (732) 367-1535
Phone: (201) 464-0008
Phone: (973) 831-5451
Phone: 908-259-8817
Phone: (973) 726-0005
Phone: (732) 431-8400
Phone: (732) 367-1535
Phone: (201) 383-4840
Phone: (301) 657-4588
Phone: (301) 685-6300
Phone: (301) 774-6136
Phone: (301) 279-7510
Phone: (860) 646-0670
Phone: (860) 527-5803
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.